Benefits
Energy metabolism
Pantothenic acid is part of coenzyme A, which the body uses to turn carbohydrates, fats and proteins into energy. People fed diets with almost no B5 developed fatigue along with other symptoms, but there is limited evidence that extra B5 raises energy in people who already get enough from food, which most people do.
Clearer facial skin with a high-dose B5 supplement
In a 12-week randomized, double-blind trial, adults with mild to moderate facial acne who took a pantothenic acid-based supplement supplying 2.2 g of B5 a day had fewer total and inflammatory blemishes than those on placebo. Only 41 people completed it, most of them women, and the product maker sponsored the study.
Hormone and cholesterol building
Through coenzyme A, pantothenic acid is involved in making cholesterol, fatty acids and steroid hormones. This is basic biochemistry that applies to anyone eating a normal diet; no study cited here shows that extra B5 changes hormone or cholesterol levels.
Neurotransmitter production
Coenzyme A made from pantothenic acid takes part in the synthesis of several neurotransmitters. No trial cited here tested B5 supplements for memory, mood or nerve function in people.
Mechanism of action
Precursor to coenzyme A (CoA)
Pantothenic acid is converted into coenzyme A, which carries acetyl and acyl groups in enzyme reactions. As acetyl-CoA it feeds the citric acid cycle that produces ATP, and CoA is needed both to build and to break down fatty acids.
Acyl carrier protein
Pantothenic acid is also part of acyl carrier protein, whose main role is fatty acid synthesis.
Hormone and cholesterol synthesis
CoA is required to make cholesterol and the steroid hormones built from it.
Neurotransmitter production
Through CoA, pantothenic acid takes part in the synthesis of several neurotransmitters.
Clinical trials
Randomized, double-blind, placebo-controlled trial of a pantothenic acid-based supplement (Pantothen) supplying 2.2 g of pantothenic acid a day, taken as two tablets twice daily with food for 12 weeks. Sponsored by the product's marketer. (Yang et al. 2014, Dermatol Ther (Heidelb))
48 adults with mild to moderate facial acne enrolled and 41 were evaluable (20 supplement, 21 placebo; 36 women).
Total facial lesion count fell more with the supplement than with placebo at week 12 (P=0.0197). Inflammatory lesions and skin-related quality of life scores also improved more than with placebo. There were minimal adverse events and no changes in blood counts or liver tests. One small, short, sponsor-funded trial.